Biogenesis Ltd and Biogenesis Inc.

Meridian Corporate Finance LLP (“MCF”) advised Management on the sale of Poole based Biogenesis Limited and USA based Biogenesis Inc to MorphoSys AG, a quoted company on the Frankfurt Stock Exchange.

The £5.25m sale was concluded in a little over 12 weeks. The acquisition establishes MorphoSys as one of the top five European suppliers of antibodies to the science research community.

John Coward, the previous Managing Director of Biogenesis Limited has become Chairman of the UK subsidiary. Commenting on the transaction John says, “The team at MCF have helped us achieve the best possible deal in a relatively short space of time. The negotiations have been fast paced and fraught at times, but the quality of advice and personal attention has been excellent throughout the process”.

Darren Thompson a director of MCF said, “The acquisition of Biogenesis Limited and it’s sister company Biogenesis Inc is a great move for the German quoted company. We have significant experience in managing complex transactions of this nature and this demonstrates that international deals can be managed locally”.